ERBB2 and breast cancer: Interestingly, previous literature showed that HER2-low/HR+ tumors presented better progression-free interval (PFI) and disease-free interval (DFI) compared to HER2-low/HR− BC, and it further underlines the heterogeneity existing within the HER2-low group [22].